Coldstream Wins NCI Contract

Coldstream Laboratories, Inc. has been awarded a five-year contract with the National Cancer Institute (NCI) for the program, “Development and Production of Parenteral Dosage Forms for Clinical Studies.” The program’s goal is to develop and produce parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products.
 
“The requirements for this program mesh perfectly with Coldstream’s capabilities and facilities. We couldn’t be more pleased to be awarded this opportunity to work with the NCI,” said Eric W. Smart, Coldstream’s president and chief executive officer. “We work hard to ensure the highest degree of quality in everything we do and being awarded this contract indicates that we are succeeding. Being awarded this contract affords Coldstream the opportunity to continue to make an impact in the field of cancer research and help advance oncologic care for the millions of people impacted by cancer every year.”